<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416142</url>
  </required_header>
  <id_info>
    <org_study_id>701E</org_study_id>
    <nct_id>NCT01416142</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens</brief_title>
  <official_title>A Study to Evaluate the Product Performance of the PureVision®2 HD Contact Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the product performance of PureVision2 HD contact
      lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Screening visit (Visit 1) and one week follow-up(Visit 3)</time_frame>
    <description>Visual acuity(VA) measured at the screening visit (all eligible participants) while wearing spectacles and the VA measured at the end of study (Visit 3) 1-Week wearing PureVision2 HD lenses. VA wearing spectacles vs. VA wearing PureVision2 HD Lenses, lower the number the better the VA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preference for Test Lens</measure>
    <time_frame>During the movie (Visit 2)</time_frame>
    <description>Proportion of participants preferring the Test lens over their spectacles. Participants changed from Spectacles to PureVision Lenses or PureVision Lenses to spectacles during movie intermission.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Spectacles</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subject's habitual spectacles (updated or confirmed as correct within the last 2 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PureVision2 HD contact lenses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Currently marketed Bausch + Lomb PureVision2 HD contact lenses</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PureVision2 HD contact lenses</intervention_name>
    <description>Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.</description>
    <arm_group_label>PureVision2 HD contact lenses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectacles</intervention_name>
    <description>Spectacles to be worn throughout 1/2 of an HD movie.</description>
    <arm_group_label>Spectacles</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have physiologically normal anterior segments not exhibiting clinically significant
             biomicroscopy findings

          -  Subjects must be myopic or hyperopic and require lens correction in each eye

          -  Subjects must own a pair of spectacles and the spectacle prescription must have been
             updated or confirmed as correct within the last 2 years.

        Exclusion Criteria:

          -  Any &quot;Present&quot; finding during the slit lamp examination that, in the Investigator's
             judgment, interferes with contact lens wear.

          -  Any systemic disease affecting ocular health.

          -  Using any systemic or topical medications that will affect ocular physiology or lens
             performance.

          -  Allergic to any component in the Biotrue multi-purpose solution
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bev Barna, CCRA</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2011</study_first_posted>
  <results_first_submitted>February 13, 2013</results_first_submitted>
  <results_first_submitted_qc>November 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 25, 2013</results_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant was enrolled on 7/6/2011 and last participant exited the study 8/21/2011. Participants were enrolled from 4 ophthalmology sites in the US. Study visit 1 was the screening visit, visit 2 took place in a movie theatre and visit 3 was 1 week follow-up visit.</recruitment_details>
      <pre_assignment_details>63 eligible participants were enrolled in the crossover design study, 62 participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PureVision2 HD:Spectacles</title>
          <description>Participants:crossed over from PureVision2 HD contact lenses to spectacle wear during the movie intermission.</description>
        </group>
        <group group_id="P2">
          <title>Spectacles:PureVision2 HD</title>
          <description>Participants crossed over from spectacle wear to PureVision2 HD contact lenses during the movie intermission.</description>
        </group>
        <group group_id="P3">
          <title>PureVision2 HD</title>
          <description>Following the movie participants wore PureVision2 HD lenses on a daily wear basis for one week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cross Over at Movie Intermission</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>PureVision2 HD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inability to maintain lens wear</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Eligible Baseline Participants</population>
      <group_list>
        <group group_id="B1">
          <title>All Eligible Baseline Participants</title>
          <description>Participants crossed over from PureVision2 HD contact lenses to spectacle wear during the movie intermission. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>Visual acuity(VA) measured at the screening visit (all eligible participants) while wearing spectacles and the VA measured at the end of study (Visit 3) 1-Week wearing PureVision2 HD lenses. VA wearing spectacles vs. VA wearing PureVision2 HD Lenses, lower the number the better the VA.</description>
        <time_frame>Screening visit (Visit 1) and one week follow-up(Visit 3)</time_frame>
        <population>Mean scores are based on the number of eyes with nonmissing logMAR VAs. All eligible, dispensed eyes while wearing spectacles vs. wearing PureVision2 lenses.</population>
        <group_list>
          <group group_id="O1">
            <title>PureVision2 Lenses</title>
            <description>The currently marketed Bausch + Lomb PureVision2 HD contact lenses. Bausch + Lomb Biotrue® multi-purpose solution was dispensed with the lenses. The lower the mean logMAR the better the VA.</description>
          </group>
          <group group_id="O2">
            <title>Spectacles</title>
            <description>The subject's habitual spectacles (updated or confirmed as correct within the last 2 years).</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Visual acuity(VA) measured at the screening visit (all eligible participants) while wearing spectacles and the VA measured at the end of study (Visit 3) 1-Week wearing PureVision2 HD lenses. VA wearing spectacles vs. VA wearing PureVision2 HD Lenses, lower the number the better the VA.</description>
          <population>Mean scores are based on the number of eyes with nonmissing logMAR VAs. All eligible, dispensed eyes while wearing spectacles vs. wearing PureVision2 lenses.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" spread="0.074"/>
                    <measurement group_id="O2" value="-0.043" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preference for Test Lens</title>
        <description>Proportion of participants preferring the Test lens over their spectacles. Participants changed from Spectacles to PureVision Lenses or PureVision Lenses to spectacles during movie intermission.</description>
        <time_frame>During the movie (Visit 2)</time_frame>
        <population>All eligible, dispensed subjects</population>
        <group_list>
          <group group_id="O1">
            <title>PureVision2 Lenses</title>
            <description>The currently marketed Bausch + Lomb PureVision2 HD contact lenses. Bausch + Lomb Biotrue® multi-purpose solution was dispensed with the lenses.</description>
          </group>
          <group group_id="O2">
            <title>Spectacles</title>
            <description>The subject's habitual spectacles (updated or confirmed as correct within the last 2 years).</description>
          </group>
          <group group_id="O3">
            <title>No Difference</title>
            <description>Participants reporting no difference between the PureVision2 HD lens and spectacles</description>
          </group>
        </group_list>
        <measure>
          <title>Preference for Test Lens</title>
          <description>Proportion of participants preferring the Test lens over their spectacles. Participants changed from Spectacles to PureVision Lenses or PureVision Lenses to spectacles during movie intermission.</description>
          <population>All eligible, dispensed subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>If a choice, would you prefer glasses or contacts?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Which were more comfortable to wear?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Which provided you with superior vision?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Which made the experience more enjoyable?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PureVision2 Lenses</title>
          <description>The currently marketed Bausch + Lomb PureVision2 HD contact lenses. Bausch + Lomb Biotrue® multi-purpose solution was dispensed with the lenses.</description>
        </group>
        <group group_id="E2">
          <title>Spectacles</title>
          <description>The subject's habitual spectacles (updated or confirmed as correct within the last 2 years).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Reindel</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>(585) 338-8129</phone>
      <email>william.reindel@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

